Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D05QJY
|
|||
Drug Name |
PMID29649907-Compound-9
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
ENANTA PHARMACEUTICALS, INC
|
|||
Structure |
Download2D MOL |
|||
Formula |
C26H44N4O2
|
|||
Canonical SMILES |
CCC1C2CC(CCC2(C3CCC4(C(C3C1O)CCC4C(C)CCC5=NNN=N5)C)C)O
|
|||
InChI |
1S/C26H44N4O2/c1-5-17-21-14-16(31)10-12-26(21,4)20-11-13-25(3)18(7-8-19(25)23(20)24(17)32)15(2)6-9-22-27-29-30-28-22/h15-21,23-24,31-32H,5-14H2,1-4H3,(H,27,28,29,30)/t15-,16-,17-,18-,19?,20?,21+,23?,24-,25-,26-/m1/s1
|
|||
InChIKey |
NGMMYLUHCOHSOR-AMGBFIHRSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Farnesoid X-activated receptor (FXR) | Target Info | Agonist | [1] |
Target's Patent Info | Farnesoid X-activated receptor (FXR) | Target's Patent Info | [1] | |
KEGG Pathway | Bile secretion | |||
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
Reactome | Recycling of bile acids and salts | |||
PPARA activates gene expression | ||||
Endogenous sterols | ||||
WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
Nuclear Receptors Meta-Pathway | ||||
Farnesoid X Receptor Pathway | ||||
Drug Induction of Bile Acid Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.